Chronic Lymphocytic Leukemia Clinical Trial
Official title:
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
Allogeneic hematopoetic stem cell transplantation (SCT) is frequently complicated by life
threatening viral reactivation. Conventional antiviral therapy is suboptimal for
cytomegalovirus (CMV), adenovirus (AdV) and Epstein-Barr virus (EBV) and nonexistent for BK
virus (BKV). An alternative approach to prevent viral reactivation is to infuse
virus-specific cytotoxic T cells (CTL) prepared from the donor early after SCT. Such
multivirus-specific CTL cells (MVST) have been successfully used in a number of centers to
prevent or treat CMV, Ad and EBV. Activity of BKV-reactive cells has not been studied. Multi
virus-specific T cells (MVST) are donor lymphocytes that are highly enriched for viral
antigens and expanded in vitro before infusion into the transplant recipient. Viral
reactivation is a particular problem inT cell depleted SCT. Median time to CMV reactivation
is estimated as 28 days post T-depleted transplant, but infusion of MVST within the immediate
post-SCT period has not been previously studied. This protocol will be the first of a planned
series of cellular therapies to be layered on our existing T lymphocyte depleted transplant
platform protocol 13-H-0144.
The aim of this study is to determine the safety and efficacy of very early infusion of MVST
directed against the four most common viruses causing complications after T-depleted SCT.
GMP-grade allogeneic MVST from the stem cell donor will be generated using monocyte-derived
donor dendritic cells (DCs) pulsed with overlapping peptide libraries of immunodominant
antigens from CMV, EBV, Ad, and BKV and expanded in IL-7 and IL-15 followed by IL-2 for 10-14
days. A fraction of the routine donor leukapheresis for lymphocytes obtained prior to stem
cell mobilization will be used to generate the MVST cells. MVST passing release criteria will
be cryopreserved ready for infusion post SCT.
Eligible subjects on NHLBI protocol 13-H-0144 will receive a single early infusion of MVST
within 30 days (target day +14, range 0-30 days) post SCT. Phase I safety monitoring will
continue for 6 weeks. Viral reactivation (CMV, EBV, Ad, BK) will be monitored by PCR by
serial blood sampling. The only antiviral prophylaxis given will be acyclovir to prevent
herpes simplex and varicella zoster reactivation. Subjects with rising PCR exceeding
threshold for treatment, or those with clinically overt viral disease will receive
conventional antiviral treatment. Patients developing acute GVHD will receive standard
treatment with systemic steroids. These patients are eligible for reinfusion of MVST when
steroids are tapered.
The clinical trial is designed as a single institution, open label, non-randomized Phase I/II
trial of MVST in transplant recipients, designed as 3-cohort dose escalation Phase I followed
by a 20 subject extension Phase II at the maximum tolerated dose of cells. Safety will be
monitored continuously for a period of 6 weeks post T cell transfer. The primary safety
endpoint will be the occurrence of dose limiting toxicity, defined as the occurrence of Grade
IV GVHD or any other SAE that is deemed to be at least probably or definitely related to the
investigational product. The primary efficacy endpoint for the phase II will be the
proportion of CMV reactivation requiring treatment at day 100 post transplant. Secondary
endpoints are technical feasibility of MSVT manufacture, patterns of virus reactivation by
PCR, and clinical disease from EBV, Ad, BK, day 100 non-relapse mortality.
Allogeneic hematopoetic stem cell transplantation (SCT) is frequently complicated by life
threatening viral reactivation. Conventional antiviral therapy is suboptimal for
cytomegalovirus (CMV), adenovirus (AdV) and Epstein-Barr virus (EBV) and nonexistent for BK
virus (BKV). An alternative approach to prevent viral reactivation is to infuse
virus-specific cytotoxic T cells (CTL) prepared from the donor early after SCT. Such
multivirus-specific CTL cells (MVST) have been successfully used in a number of centers to
prevent or treat CMV, Ad and EBV. Activity of BKV-reactive cells has not been studied. Multi
virus-specific T cells (MVST) are donor lymphocytes that are highly enriched for viral
antigens and expanded in vitro before infusion into the transplant recipient. Viral
reactivation is a particular problem inT cell depleted SCT. Median time to CMV reactivation
is estimated as 28 days post T-depleted transplant, but infusion of MVST within the immediate
post-SCT period has not been previously studied. This protocol will be the first of a planned
series of cellular therapies to be layered on our existing T lymphocyte depleted transplant
platform protocol 13-H-0144.
The aim of this study is to determine the safety and efficacy of very early infusion of MVSTr
cells directed against the four most common viruses causing complications after T-depleted
SCT. GMP-grade allogeneic MVSTr from the stem cell donor will be generated using or
peripheral blood mononuclear cells (PBMCs) pulsed with overlapping peptide libraries of
immunodominant antigens from CMV, EBV, Ad, and BKV and expanded in IL-7 and IL-15 followed by
IL-2 for 14 days. A fraction of the routine donor leukapheresis for lymphocytes obtained
prior to stem cell mobilization will be used to generate the MVST cells. MVST passing release
criteria will be cryopreserved ready for infusion post SCT.
Eligible subjects on NHLBI protocol 13-H-0144 will receive a single early infusion of MVSTr
on day +7 post transplant range 0-14 days) post SCT. Phase I safety monitoring will continue
for 6 weeks after infusion. Viral reactivation (CMV, EBV, Ad, BK) will be monitored by PCR by
serial blood sampling. The only antiviral prophylaxis given will be acyclovir to prevent
herpes simplex and varicella zoster reactivation. Subjects with rising PCR exceeding
threshold for treatment, or those with clinically overt viral disease will receive
conventional antiviral treatment. Patients developing acute GVHD will receive standard
treatment with systemic steroids. These patients are eligible for reinfusion of MVST when
steroids are tapered.
The clinical trial is designed as a single institution, open label, non-randomized Phase I
trial of MVSTr in transplant recipients, designed as a single cohort Phase I study. Safety
will be monitored continuously for a period of 6 weeks post MVSTr transfer. The primary
safety endpoint will be the occurrence of dose limiting toxicity (DLT), defined as the
occurrence of Grade IV GVHD, Grade III cytokine release syndrome (CRS), Grade III
autoimmunity or any other SAE that is deemed to be at least probably or definitely related to
the investigational product.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Active, not recruiting |
NCT04240704 -
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
|
Phase 1 | |
Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03280160 -
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
|
Phase 2 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Recruiting |
NCT05417165 -
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT04028531 -
Understanding Chronic Lymphocytic Leukemia
|
||
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01527045 -
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
Recruiting |
NCT04679012 -
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
|
Phase 2 | |
Recruiting |
NCT05405309 -
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05023980 -
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Terminated |
NCT04189952 -
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
|
Phase 2 |